SMS Pharmaceuticals Ltd

AGM Details

• Meeting held via VC/OAVM; all agenda items approved by members.
• Shareholder eligibility cut-off and remote e-voting deadline noted.
• No physical meeting or proxy arrangement; meeting conducted remotely.

Key Resolutions & outcomes

• Adopt standalone and consolidated financial statements; passed with 99.88% in favour.
• Declaration of dividend on equity shares; passed with 99.89% in favour.
• Re-appointment of director retiring by rotation; passed with 99.89% in favour.
• Approval of material related party transactions with a related private company; passed 99.30% in favour.
• Remuneration payable to Cost Auditors for 2026-27; passed 99.89% in favour.
• Special: Re-appointment of CMD and fixation of remuneration; passed 99.43% in favour.
• Special: Provide loan to subsidiary company; passed 99.30% in favour.

Dividend Details

• Dividend on equity shares approved for the year; per-share amount not disclosed.

Directors & Appointments

• Re-appointment of director retiring by rotation; approved.
• Appointment of Chairman and Managing Director; remuneration fixed and approved.

AGM details and outcomes

• AGM held on 29 September 2026 at 10:30 AM via VC/OAVM.
• Resolution 1: Adoption of standalone and consolidated financial statements approved.
• Resolution 2: Dividend on equity shares for FY2025-26 approved.
• Resolution 3: Re-appointment of Dr. Sunkara Venkata Satya Shiva Prasad approved.
• Resolution 4: Approval of material related party transactions with VKT Pharma Private Limited.
• Resolution 5: Remuneration to Cost Auditors for FY2026-27 approved.
• Resolution 6: Re-appointment of Ramesh Babu Potluri as CMD approved; remuneration fixed.
• Resolution 7: Special resolution to provide loan to SMS Peptides Private Limited approved.
• All resolutions passed with requisite majority.

AGM Details

• Date: 29 September 2026.
• Time: 10:30 a.m. IST.
• Mode: VC/OAVM.
• Quorum present; proxies not applicable due to VC/OAVM.

Resolutions

• Adoption of Audited Standalone and Consolidated Financial Statements for FY2025-26 (Ordinary).
• Declaration of dividend on Equity shares for FY2025-26 (Ordinary).
• Re-appointment of Dr. Sunkara Venkata Satya Shiva Prasad on rotation (Ordinary).
• Approval of material related party transactions with VKT Pharma Private Limited (Ordinary).
• Approval for remuneration payable to the Cost Auditors for FY2026-27 (Ordinary).
• Re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director; fixation of remuneration (Special).
• Approval to provide loan to SMS Peptides Private Limited, Subsidiary Company (Special).

Auditors & Scrutinizer

• Statutory Auditor: M/s Suryanarayana & Suresh Chartered Accountants.
• Internal Auditor: M/s Adusumilli and Associates.
• Scrutinizer: M/s CSB Associates, Company Secretaries.

Directors & Management

• Re-appointment of Dr. Sunkara Venkata Satya Shiva Prasad on retirement by rotation (Ordinary).
• Re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director; remuneration fixation (Special).

Voting Status

• Voting results to be declared within two working days; combined remote and AGM voting to be reported.

AGM Details

• Date and time: 29 September 2026 at 10:30 a.m. IST.
• Mode: video conference / other audio-visual means (VC/OAVM).

Key Resolutions

• Ordinary: Adoption of audited standalone and consolidated financial statements for FY 2025-26.
• Ordinary: Declaration of dividend on equity shares for FY 2025-26.
• Ordinary: Re-appointment of Dr. Sunkara Venkata Satya Shiva Prasad on rotation.
• Ordinary: Approval of material related party transactions with VKT Pharma Private Limited.
• Ordinary: Approval for remuneration to Cost Auditors for FY 2026-27.
• Special: Re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director; remuneration.
• Special: Approval to provide loan to SMS Peptides Private Limited (subsidiary).

Voting Status

• Results to be announced within two working days; Scrutinizer's report to be countersigned.

Dividend

• Dividend declaration on equity shares (amount not disclosed).

Directors & Management

• Re-appointment of Dr. Sunkara Venkata Satya Shiva Prasad (DIN 10404277).

Auditors

• Statutory Auditor: M/s Suryanarayana & Suresh Chartered Accountants.
• Internal Auditor: M/s Adusumilli and Associates.
• Scrutinizer: M/s CSB Associates, Company Secretaries.

Material Related Party Transactions

• Approval of material RPT with VKT Pharma Private Limited; value not disclosed.

Meeting Details

• Date: 15 September 2026; Venue: Hyderabad; Group meet (physical).
• Organizer: Emkay Global Investors Meeting.
• Company participants: management team.
• Purpose: analyst/institutional investor interaction.

Rating Action

• Long-term rating CARE A; Stable; outlook revised from Positive.
• Short-term rating CARE A1; reaffirmed.
• Outlook revised from Positive to Stable.

Facilities & Amounts

• Total long-term facilities: Rs 570.07 crore.
• Total short-term facilities: Rs 52.83 crore.
• Lenders include EXIM Bank of India, Axis Bank, SBI, IDBI Bank, RBL Bank.

Rationale

• Based on FY26 audited and Q1FY27 abridged performance.